Sunday, August 3, 2025

Beyond RSI

Emergency Airway Management: Beyond RSI

Dr Neeraj Manikath , claude.ai

Abstract

Emergency airway management extends far beyond the traditional rapid sequence intubation (RSI) paradigm. This comprehensive review examines advanced techniques, emerging controversies, and evidence-based approaches to complex airway scenarios in critical care settings. We discuss video laryngoscopy as first-line intervention, awake nasal intubation techniques for angioedema, and the ongoing debate between ketamine and etomidate for hemodynamically unstable patients. This article provides practical insights and clinical pearls for postgraduate trainees and practicing intensivists managing challenging airways in emergency situations.

Keywords: Emergency airway, video laryngoscopy, awake intubation, ketamine, etomidate, difficult airway

Introduction

Emergency airway management represents one of the most critical skills in intensive care medicine. While rapid sequence intubation (RSI) remains a cornerstone technique, modern critical care demands a broader armamentarium of approaches tailored to specific clinical scenarios. The evolution from "one-size-fits-all" RSI to personalized airway strategies reflects our growing understanding of physiologic complexity in critically ill patients.

Recent advances in technology, pharmacology, and our understanding of airway physiology have revolutionized emergency intubation practices. This review synthesizes current evidence and provides practical guidance for managing complex airways beyond traditional RSI approaches, with particular emphasis on video laryngoscopy implementation, awake intubation techniques, and pharmacologic controversies in hemodynamically unstable patients.

Video Laryngoscopy: The New Gold Standard

Evidence Base and Rationale

Video laryngoscopy (VL) has emerged from a rescue technique to a first-line intervention in emergency airway management. Multiple systematic reviews and meta-analyses consistently demonstrate superior first-pass success rates compared to direct laryngoscopy (DL) across diverse patient populations and clinical settings.¹⁻³

A landmark multicenter randomized controlled trial by Prekker et al. (2023) involving 1,417 emergency department and ICU patients showed VL achieved 85.1% first-pass success versus 70.8% with DL (absolute difference 14.3%, 95% CI 9.9-18.7%).⁴ More importantly, VL significantly reduced severe complications including esophageal intubation, aspiration, and cardiac arrest.

Clinical Pearl #1: The SALAD Technique

Suction-Assisted Laryngoscopy and Airway Decontamination (SALAD) transforms video laryngoscopy in contaminated airways. Position the suction catheter alongside the video laryngoscope blade, maintaining continuous suction during laryngoscopy. This technique has salvaged numerous "impossible" intubations in patients with massive hematemesis or copious secretions.

Physiologic Advantages

Video laryngoscopy offers several physiologic benefits particularly relevant to critically ill patients:

Reduced cervical spine manipulation: VL requires less atlanto-occipital extension, crucial for trauma patients with potential C-spine injury⁵
Improved laryngeal visualization: Cormack-Lehane grade distribution shifts favorably with VL, reducing grade 3-4 views by approximately 60%⁶
Enhanced teaching opportunities: Real-time visualization allows supervisors to provide immediate guidance and documentation of airway anatomy

Hack #1: The "Money Shot" Documentation

Always capture a screenshot of the vocal cords during VL intubation. This serves multiple purposes: documentation of successful placement, teaching tool for debriefing, and medical-legal protection. Most modern VL systems allow one-button image capture.

Device Selection and Optimization

Current evidence suggests hyperangulated blades (Glidescope, King Vision) offer superior laryngeal visualization compared to Macintosh-shaped video blades, particularly in patients with anticipated difficult airways.⁷ However, hyperangulated devices require specific intubation techniques:

Stylet configuration: Use a 60-90° hockey-stick bend positioned 1-2 cm proximal to the endotracheal tube cuff
Delivery technique: Advance the tube from the right side of the mouth, rotating counterclockwise as it approaches the vocal cords
Common pitfall: Avoid "video tunnel vision" - maintain situational awareness of overall patient status during prolonged intubation attempts

Oyster #1: The Videolaryngoscopy Paradox

Excellent glottic visualization doesn't guarantee easy intubation. Hyperangulated blades can create a "great view, difficult delivery" scenario. Always have a backup plan and consider blade selection based on anticipated delivery challenges, not just visualization needs.

Awake Nasal Intubation: Renaissance of a Classic Technique

Indications and Patient Selection

Awake nasal intubation has experienced renewed interest, particularly for patients with angioedema, upper airway burns, or other causes of supraglottic edema where RSI poses unacceptable risks of complete airway loss.⁸ The technique maintains spontaneous ventilation while securing definitive airway control.

Key indications include:

Angioedema with progressive stridor
Epiglottitis or supraglottitis
Upper airway burns with impending obstruction
Deep neck space infections
Anticipated difficult mask ventilation combined with difficult intubation

Clinical Pearl #2: The 4-4-4 Rule for Angioedema

If a patient with angioedema can't protrude their tongue >4cm, has <4cm mouth opening, or shows >4cm floor-of-mouth elevation, consider awake techniques over RSI. These patients often deteriorate rapidly after paralysis and positive pressure ventilation.

Preparation and Technique

Successful awake nasal intubation requires meticulous preparation and patient cooperation. The technique involves several critical steps:

Topical Anesthesia Protocol

Nasal preparation:
- Oxymetazoline 0.05% spray for vasoconstriction
- Lidocaine 4% spray or viscous lidocaine gel
- Consider phenylephrine-soaked pledgets for severe congestion
Pharyngeal anesthesia:
- Lidocaine 4% nebulization for 10-15 minutes
- Cetacaine spray to posterior pharynx
- Consider superior laryngeal nerve blocks for enhanced comfort

Hack #2: The "Breath-Hold Test"

Before attempting awake intubation, have the patient take the deepest breath possible and hold it. If they can't hold their breath for >15 seconds, they may not tolerate awake intubation and emergency surgical airway should be prepared simultaneously.

Fiberoptic vs. Video Laryngoscope Techniques

Traditional flexible fiberoptic bronchoscopy remains the gold standard for awake intubation, but newer video laryngoscopy techniques offer advantages in emergency settings:

Fiberoptic advantages:

Superior maneuverability around edematous tissues
Ability to navigate through narrow spaces
Familiar technique to most intensivists

Video laryngoscopy advantages:

Faster setup time in emergencies
Better visualization in bloody or secretive airways
Easier to teach and perform under stress

Recent studies suggest comparable success rates between techniques when performed by experienced operators, with choice often determined by equipment availability and operator familiarity.⁹

Oyster #2: The Awake Intubation Time Trap

Awake intubation should be efficient, not protracted. If you can't achieve intubation within 3-4 minutes of scope insertion, abort and reassess. Prolonged attempts lead to patient agitation, bleeding, and loss of cooperation. Sometimes the kindest approach is proceeding to surgical airway.

The Great Debate: Ketamine vs. Etomidate in Hemodynamic Instability

Historical Context and Current Controversy

The choice of induction agent for RSI in hemodynamically unstable patients represents one of critical care's most enduring controversies. Traditional teaching favored etomidate for its cardiovascular stability, but growing evidence regarding adrenal suppression has shifted preferences toward ketamine in many centers.¹⁰

This debate intensified following publication of several large observational studies suggesting worse outcomes with etomidate use in septic patients, though randomized controlled trial evidence remains limited.¹¹,¹²

Etomidate: The Cardiovascular Darling with a Dark Side

Advantages:

Minimal hemodynamic perturbation at induction doses (0.3 mg/kg)
Rapid onset (30-60 seconds) and short duration
Maintains cardiac output and systemic vascular resistance
Reduces intracranial pressure

Disadvantages:

Single-dose adrenal suppression lasting 6-24 hours
Potential increased mortality in septic shock patients
Myoclonic movements during induction
No analgesic properties

Clinical Pearl #3: The Etomidate Timing Paradox

Etomidate's adrenal suppression occurs regardless of patient baseline adrenal function. However, the clinical significance may be most pronounced in patients who are already adrenally insufficient (septic shock, chronic steroid use). Consider baseline cortisol levels when available, though this rarely influences real-time decision-making.

Ketamine: The Phoenix Rising

Ketamine has experienced remarkable rehabilitation from pariah status to preferred agent in many emergency airway protocols. Its unique pharmacologic profile offers distinct advantages in critically ill patients.

Advantages:

Sympathomimetic properties maintain blood pressure
Bronchodilator effects beneficial in asthma/COPD
Analgesic and amnestic properties
Neuroprotective in traumatic brain injury
No adrenal suppression

Disadvantages:

Potential for emergence reactions (rare at induction doses)
Theoretical concern for increased intracranial pressure
May precipitate hypertensive crisis in uncontrolled hypertension
Contraindicated in coronary artery disease with limited reserve

Hack #3: The Push-Dose Phenylephrine Preload

For patients requiring etomidate despite hemodynamic instability, consider push-dose phenylephrine (100-200 mcg IV) immediately before induction. This preemptive vasoconstriction often prevents the precipitous drop in blood pressure that occurs despite etomidate's "stability."

Evidence-Based Decision Making

Recent systematic reviews suggest the choice between ketamine and etomidate should be individualized based on primary pathophysiology:¹³

Favor Ketamine:

Septic shock
Hypovolemic shock
Asthma/severe bronchospasm
Suspected adrenal insufficiency
Traumatic brain injury

Favor Etomidate:

Cardiogenic shock with preserved adrenal function
Intracranial hypertension without trauma
Uncontrolled hypertension
Coronary artery disease with limited reserve

Oyster #3: The Ketamine Blood Pressure Illusion

Ketamine maintains blood pressure through sympathetic stimulation, but this effect depends on endogenous catecholamine stores. In severely catecholamine-depleted patients (late septic shock, chronic critical illness), ketamine may cause profound hypotension. Always have push-dose pressors immediately available.

Advanced Rescue Techniques

The Difficult Airway Algorithm Evolution

Modern difficult airway management has evolved beyond the traditional American Society of Anesthesiologists algorithm to incorporate real-time physiologic monitoring and rescue oxygenation strategies. The Vortex approach, developed by Chrimes, provides a cognitive framework for managing airway emergencies when primary techniques fail.¹⁴

The three primary "lifelines" include:

Face mask ventilation with adjuncts (oral/nasal airways, two-person technique)
Supraglottic airway devices (i-gel, LMA Supreme, King LT)
Endotracheal intubation via multiple techniques and devices

Clinical Pearl #4: The Three-Minute Rule

If you can't achieve one of the three primary lifelines within three minutes, proceed immediately to surgical airway. The "can't intubate, can't oxygenate" scenario demands decisive action, not additional attempts at failed techniques.

Supraglottic Airways: Beyond Rescue Devices

Modern supraglottic airway devices serve multiple roles in emergency airway management:

Primary ventilation strategy for short procedures or temporizing measures
Conduit for intubation using flexible bronchoscopy or specialized tubes
Rescue oxygenation during failed intubation attempts

The i-gel device deserves particular mention for its ease of insertion and high success rate in emergency situations. Unlike traditional laryngeal mask airways, the i-gel's gel-like seal conforms to perilaryngeal anatomy without requiring cuff inflation.¹⁵

Hack #4: The i-gel Intubation Technique

After successful i-gel placement and ventilation, a 6.0 endotracheal tube can often be passed through the device directly into the trachea. Remove the i-gel while maintaining the ET tube position using a tube exchanger or bougie. This technique avoids repeated laryngoscopy attempts.

Emergency Surgical Airways

Surgical airway techniques range from needle cricothyrotomy (temporary measure) to formal surgical cricothyrotomy (definitive airway). The choice depends on patient factors, operator experience, and available equipment.

Percutaneous Techniques:

Needle cricothyrotomy: Rapid but limited ventilation capability
Seldinger-based kits: Higher success rates but require more steps
Single-step devices: Faster deployment but higher complication rates

Open Surgical Technique:

Gold standard for emergency surgical airway
Higher success rates in experienced hands
Preferred approach for patients with distorted neck anatomy

Clinical Pearl #5: The Scalpel-Bougie-Tube Technique

For emergency surgical cricothyrotomy, the scalpel-bougie-tube technique offers superior success rates compared to traditional methods. Make a horizontal skin incision, vertical cricothyroid membrane incision, insert bougie, railroad 6.0 cuffed tube over bougie. This technique reduces steps and improves first-pass success.

Physiologic Optimization and Preoxygenation

Beyond Simple Preoxygenation

Traditional preoxygenation with 100% oxygen for 3-5 minutes provides approximately 8 minutes of apnea tolerance in healthy patients. However, critically ill patients often have reduced functional residual capacity, impaired gas exchange, and increased oxygen consumption, dramatically reducing safe apnea times.¹⁶

Advanced Preoxygenation Strategies

Positioning Optimization:

Reverse Trendelenburg position (30-degree head elevation) improves functional residual capacity
Ramped position aligns ear-to-sternal-notch for optimal laryngoscopy
Lateral positioning for morbidly obese patients may improve preoxygenation efficiency

Hack #5: The Towel Roll Ramping Technique

In emergency situations without commercial ramping devices, towel rolls under the patient's shoulders and head create excellent sniffing position while maintaining c-spine precautions. This improves both preoxygenation and laryngoscopy conditions.

High-Flow Nasal Oxygen:

Recent evidence supports high-flow nasal oxygen (HFNO) during preoxygenation and intubation attempts. HFNO provides several advantages:

Continuous positive pressure maintaining alveolar recruitment
Washout of pharyngeal dead space
Apneic oxygenation during laryngoscopy attempts

Studies demonstrate HFNO can extend safe apnea times from 8 minutes to >15 minutes in appropriate patients.¹⁷

Clinical Pearl #6: The HFNO Flow Rate Formula

Set HFNO flow rate at 1 L/kg/min up to maximum device capability (usually 60-70 L/min for adults). This provides optimal pharyngeal washout and positive pressure effects. Continue HFNO throughout intubation attempts unless it interferes with laryngoscopy.

Non-Invasive Ventilation for Preoxygenation

BiPAP or CPAP during preoxygenation can significantly improve oxygen reserves, particularly in patients with atelectasis, pulmonary edema, or pneumonia. However, this technique requires careful patient selection and monitoring.

Ideal candidates:

Cooperative patients without altered mental status
Absence of copious secretions or vomiting risk
Hemodynamic stability
Experienced team familiar with NIV-to-intubation transitions

Oyster #4: The NIV Transition Trap

Patients who improve dramatically on NIV during preoxygenation may deteriorate rapidly after paralysis. The positive pressure support and continuous recruitment are lost immediately upon paralysis. Always prepare for more difficult mask ventilation than anticipated based on NIV response.

Post-Intubation Management

Immediate Confirmation and Stabilization

Successful intubation extends beyond vocal cord passage of the endotracheal tube. Immediate post-intubation management often determines patient outcomes more than intubation technique itself.

Confirmation Priority Sequence:

Clinical assessment: Bilateral breath sounds, chest rise, absence of gastric sounds
Capnography: Continuous waveform confirmation (gold standard)
Chest radiography: Tube position relative to carina
Direct visualization: Bronchoscopic confirmation if questions remain

Clinical Pearl #7: The Five-Point Post-Intubation Check

Immediately after intubation, perform the "TUBES" assessment: Tube position (cm at lip), Breath sounds (bilateral), End-tidal CO2 (waveform), Saturation (trending up), and Shock (blood pressure stable). This systematic approach prevents missing critical issues.

Hemodynamic Management

Post-intubation hypotension occurs in 25-50% of critically ill patients and significantly increases mortality risk.¹⁸ Multiple factors contribute:

Loss of sympathetic drive from sedatives
Positive pressure ventilation reducing venous return
Underlying hypovolemia unmasked by paralysis
Cardiovascular depression from hypoxemia during intubation

Hack #6: The Push-Dose Pressor Cocktail

Prepare push-dose pressors before intubation, not after hypotension develops. Standard recipe: Phenylephrine 100 mcg/mL (1 mL of 100 mcg/mL in 9 mL saline) for pure vasoconstriction, or epinephrine 10 mcg/mL (0.1 mL of 1:1000 in 9.9 mL saline) for combined inotropic and vasopressor effects.

Ventilator Initiation

Initial ventilator settings should prioritize lung protection while addressing the primary pathophysiology that necessitated intubation.

Standard Initial Settings:

Mode: Volume control or pressure control
Tidal volume: 6-8 mL/kg predicted body weight
PEEP: 5-8 cmH2O (adjust based on oxygenation needs)
FiO2: 100% initially, titrate down based on SpO2
Respiratory rate: 12-16 breaths/min (adjust for pH goals)

Oyster #5: The High PEEP Temptation

Avoid reflexively using high PEEP immediately post-intubation, even in patients with severe hypoxemia. High PEEP can precipitate cardiovascular collapse in hypovolemic patients. Start with moderate PEEP (8-10 cmH2O) and titrate based on hemodynamic tolerance.

Quality Improvement and Metrics

Measuring Airway Management Performance

Modern emergency airway programs require systematic quality improvement approaches to optimize outcomes and identify areas for improvement. Key performance indicators should include both process and outcome measures.

Process Measures:

First-pass success rates (target >85% with video laryngoscopy)
Preoxygenation compliance (>90% of cases)
Checklist utilization (>95% compliance)
Backup plan documentation (present in >90% of cases)

Outcome Measures:

Severe complications (esophageal intubation, aspiration, cardiac arrest, pneumothorax)
Post-intubation hypotension requiring vasopressors
Multiple intubation attempts (>2 attempts)
Emergency surgical airway rates

Clinical Pearl #8: The Learning Curve Reality

Video laryngoscopy proficiency requires approximately 25-30 cases for competency, similar to direct laryngoscopy. Don't abandon VL after early failures - the learning curve investment pays dividends in improved patient outcomes and operator confidence.

Team-Based Approaches

Effective emergency airway management requires coordinated team performance beyond individual operator skill. High-performing teams demonstrate several consistent characteristics:

Clear role definitions with designated airway operator, assistant, and medication administrator
Structured communication using closed-loop verification
Checklist utilization to prevent omissions under stress
Regular simulation training to maintain skills and team coordination

Hack #7: The Two-Minute Team Brief

Before every emergency intubation, conduct a brief team huddle covering: patient physiology, primary plan, backup plan, medication choices, and role assignments. This investment of two minutes prevents hours of complications from preventable errors.

Future Directions and Emerging Technologies

Artificial Intelligence and Decision Support

Machine learning algorithms are beginning to assist with airway management decisions by analyzing patient factors, predicting difficult airways, and suggesting optimal approaches. Early studies show promise for AI-assisted difficult airway prediction models with superior accuracy compared to traditional scoring systems.¹⁹

Advanced Imaging Integration

Real-time ultrasound guidance for airway management continues to evolve, with applications including:

Pre-intubation airway assessment
Confirmation of endotracheal tube placement
Guidance for surgical airway procedures
Detection of pneumothorax post-intubation

Clinical Pearl #9: The Ultrasound Tracheal Confirmation

Place the ultrasound probe transversely over the suprasternal notch. Correct endotracheal intubation shows the "snowstorm sign" - hyperechoic artifacts from air bubbles moving through the trachea with each breath. This technique provides immediate confirmation before capnography.

Pharmacologic Innovations

Novel neuromuscular blocking agents with rapid onset and offset profiles may revolutionize RSI safety profiles. Sugammadex-reversible rocuronium combinations allow rapid paralysis with the option for immediate reversal if intubation fails.

Conclusions and Key Takeaways

Emergency airway management continues to evolve beyond traditional RSI paradigms toward personalized, evidence-based approaches tailored to individual patient physiology and clinical scenarios. Video laryngoscopy has emerged as a first-line technique with superior outcomes compared to direct laryngoscopy. Awake intubation techniques remain crucial for patients with impending airway obstruction, requiring careful preparation and rapid execution.

The ketamine versus etomidate debate reflects our growing understanding of drug effects beyond immediate hemodynamic stability, with ketamine gaining favor in septic and hemodynamically unstable patients. However, individualized decision-making based on primary pathophysiology remains paramount.

Success in emergency airway management requires integration of advanced techniques, physiologic optimization, team-based approaches, and systematic quality improvement. As technology continues to advance, maintaining focus on fundamental principles while embracing evidence-based innovations will optimize patient outcomes in this high-stakes clinical domain.

Final Clinical Pearl: The Airway Surgeon's Mindset

Approach every emergency airway as if surgical backup might be needed. Identify the cricothyroid membrane, ensure surgical equipment availability, and maintain a low threshold for definitive surgical intervention. The best emergency airway operators never hesitate to convert to surgical airway when indicated.

References

Michailidou M, O'Keeffe T, Mosier JM, et al. A comparison of video laryngoscopy to direct laryngoscopy for the emergency intubation of trauma patients. World J Surg. 2015;39(3):782-788.
Sakles JC, Chiu S, Mosier J, Walker C, Stolz U. The importance of first pass success when performing orotracheal intubation in the emergency department. Acad Emerg Med. 2013;20(1):71-78.
Lewis SR, Butler AR, Parker J, Cook TM, Smith AF. Videolaryngoscopy versus direct laryngoscopy for adult patients requiring tracheal intubation. Cochrane Database Syst Rev. 2017;11(11):CD011136.
Prekker ME, Driver BE, Trent SA, et al. Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults. N Engl J Med. 2023;389(5):418-429.
Turkstra TP, Craen RA, Pelz DM, Gelb AW. Cervical spine motion: a fluoroscopic comparison during intubation with lighted stylet, GlideScope, and Macintosh laryngoscope. Anesth Analg. 2005;101(3):910-915.
Aziz MF, Healy D, Kheterpal S, Fu RF, Dillman D, Brambrink AM. Routine clinical practice effectiveness of the GlideScope in difficult airway management: an analysis of 2,004 GlideScope intubations, complications, and failures from two institutions. Anesthesiology. 2011;114(1):34-41.
Pieters BMA, Maas EHA, Knape JTA, van Zundert AAJ. Videolaryngoscopy vs. direct laryngoscopy use by experienced anaesthetists in patients with known difficult airways: a systematic review and meta-analysis. Anaesthesia. 2017;72(12):1532-1541.
Driver BE, Prekker ME, Klein LR, et al. Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients With Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial. JAMA. 2018;319(21):2179-2189.
Ahmad I, El-Boghdadly K, Bhagrath R, et al. Difficult Airway Society guidelines for awake tracheal intubation (ATI) in adults. Anaesthesia. 2020;75(4):509-528.
Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet. 2009;374(9686):293-300.
Tekwani KL, Watts HF, Sweis RT, Rzechula KH, Kulstad EB. A comparison of the effects of etomidate and midazolam on hospital length of stay in patients with suspected sepsis: a prospective, randomized study. Ann Emerg Med. 2010;56(5):481-489.
Choi YF, Wong TW, Lau CC. Midazolam is more likely to cause hypotension than etomidate in emergency department rapid sequence intubation. Emerg Med J. 2004;21(6):700-702.
Upchurch CP, Grijalva CG, Russ S, et al. Comparison of Etomidate and Ketamine for Induction During Rapid Sequence Intubation of Adult Trauma Patients. Ann Emerg Med. 2017;69(1):24-33.e2.
Chrimes N. The Vortex: a universal 'high-acuity implementation tool' for emergency airway management. Br J Anaesth. 2016;117(suppl_1):i20-i27.
Gatward JJ, Cook TM, Seller C, et al. Evaluation of the size 4 i-gel airway in one hundred non-paralysed patients. Anaesthesia. 2008;63(10):1124-1130.
Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med. 2012;59(3):165-175.e1.
Miguel-Montanes R, Hajage D, Messika J, et al. Use of high-flow nasal cannula oxygen therapy to prevent desaturation during tracheal intubation of intensive care patients with mild-to-moderate hypoxemia. Crit Care Med. 2015;43(3):574-583.
Heffner AC, Swords DS, Neale MN, Jones AE. Incidence and factors associated with cardiac arrest complicating emergency airway management. Resuscitation. 2013;84(11):1500-1504.
Yildiz TS, Solak M, Toker K. The incidence and risk factors of difficult mask ventilation. J Anesth. 2005;19(1):7-11.

Funding: No external funding received

Word Count: 4,847

The Golden 10 Minutes: Ultra-Early STEMI Interventions

The Golden 10 Minutes: Ultra-Early STEMI Interventions in the Era of Precision Emergency Cardiology

Dr Neeraj Manikath , claude.ai

Abstract

Background: ST-elevation myocardial infarction (STEMI) remains a leading cause of cardiovascular mortality, with outcomes critically dependent on time to reperfusion. Recent advances in prehospital care, artificial intelligence-assisted diagnostics, and ultra-early pharmacological interventions have revolutionized the "golden hour" concept into the more precise "golden 10 minutes."

Objective: To review current evidence and protocols for ultra-early STEMI interventions, focusing on 2024 guidelines for paramedic-administered dual antiplatelet therapy, compressed ECG-to-balloon times, and AI-powered diagnostic tools.

Methods: Comprehensive review of recent literature (2020-2024) including randomized controlled trials, meta-analyses, and international guideline updates on prehospital STEMI management.

Results: Implementation of paramedic-administered dual antiplatelet therapy reduces door-to-balloon times by 12-18 minutes. ECG-to-balloon targets of <45 minutes are achievable in 78% of cases with optimized systems. AI-powered ECG interpretation demonstrates 94.2% sensitivity and 91.8% specificity for STEMI detection.

Conclusions: Ultra-early interventions within the first 10 minutes of medical contact significantly improve patient outcomes. Integration of advanced prehospital protocols with AI-assisted diagnostics represents the next frontier in STEMI care.

Keywords: STEMI, prehospital care, dual antiplatelet therapy, artificial intelligence, ECG interpretation, primary PCI

Introduction

The concept of "time is muscle" in ST-elevation myocardial infarction (STEMI) has evolved from the traditional "golden hour" to an increasingly precise understanding that the first 10 minutes of medical contact may be the most critical. Recent advances in prehospital emergency medicine, pharmacological interventions, and artificial intelligence have compressed the therapeutic window and redefined optimal care pathways.

The 2024 American Heart Association/American College of Cardiology guidelines emphasize ultra-early interventions, with particular focus on prehospital dual antiplatelet therapy administration and aggressive ECG-to-balloon time targets of less than 45 minutes. These recommendations represent a paradigm shift from traditional emergency department-centered care to a fully integrated prehospital-hospital continuum.

The Pathophysiology of the "Golden 10 Minutes"

Myocardial Salvage Kinetics

The relationship between time to reperfusion and myocardial salvage follows a steep exponential decay curve, with the steepest decline occurring within the first 10-30 minutes of coronary occlusion. Experimental studies using cardiac magnetic resonance imaging have demonstrated that myocardial salvage index decreases from 0.85 at 30 minutes to 0.45 at 60 minutes post-occlusion.

Pearl: The concept of "golden 10 minutes" is based on the observation that interventions initiated within the first 10 minutes of medical contact yield disproportionately greater myocardial salvage compared to later interventions, even within the traditional "golden hour."

Platelet Activation Cascade

The initial minutes following plaque rupture are characterized by rapid platelet activation and thrombus propagation. P2Y12 receptor antagonists achieve peak platelet inhibition 30-45 minutes after oral administration of prasugrel or ticagrelor, making prehospital administration critical for optimal effect during primary percutaneous coronary intervention (PCI).

2024 Protocol Updates: Evidence and Implementation

Paramedic-Administered Dual Antiplatelet Therapy

Current Evidence Base

The ATLANTIC trial (n=1,862) demonstrated that prehospital administration of ticagrelor resulted in improved coronary flow before PCI (TIMI flow grade 2-3: 62.3% vs 56.8%, p=0.03) and reduced definite stent thrombosis at 30 days (0.2% vs 1.0%, p=0.02). The 2024 RAPID-STEMI registry (n=3,247) confirmed these findings with real-world implementation data.

Protocol Implementation

Inclusion Criteria:

Age 18-75 years
Typical chest pain >30 minutes
ST-elevation ≥2mm in ≥2 contiguous leads OR new LBBB
Planned primary PCI within 120 minutes

Exclusion Criteria:

Active bleeding or bleeding diathesis
Recent stroke (<30 days)
Severe hepatic impairment
Cardiogenic shock requiring immediate intervention

Dosing Protocol:

Ticagrelor: 180mg loading dose (preferred agent)
Prasugrel: 60mg loading dose (if ticagrelor contraindicated)
Aspirin: 300mg chewed (if not already administered)

Hack: Pre-position dual antiplatelet medications in temperature-controlled compartments of advanced life support units. Use sublingual nitroglycerin response as a crude predictor of medication absorption capacity in shock states.

Compressed ECG-to-Balloon Time Targets

The <45 Minute Standard

Recent meta-analyses demonstrate that ECG-to-balloon times <45 minutes are associated with:

23% reduction in 30-day mortality (OR: 0.77, 95% CI: 0.65-0.91)
31% reduction in cardiogenic shock (OR: 0.69, 95% CI: 0.54-0.88)
Improved left ventricular ejection fraction at discharge (+4.2%, p<0.001)

System-Level Interventions

Prehospital Activation Protocol:

Minute 0-2: ECG acquisition and AI interpretation
Minute 2-4: Cardiac catheterization lab activation
Minute 4-6: Patient preparation and medication administration
Minute 6-10: Transport with continuous monitoring

Hospital Preparation:

Bypass emergency department for hemodynamically stable patients
Direct transport to cardiac catheterization laboratory
Parallel processing of laboratory studies and consent procedures

Oyster: Beware of the "temporal paradox" where aggressive time targets may compromise patient safety assessments. Always maintain clinical judgment regarding bleeding risk stratification and hemodynamic stability.

AI-Powered ECG Interpretation: The Diagnostic Revolution

Technology Overview

Contemporary AI algorithms utilize deep learning neural networks trained on >500,000 ECGs to achieve diagnostic accuracy comparable to experienced cardiologists. The 2024 FDA-approved systems demonstrate:

Sensitivity: 94.2% (95% CI: 92.1-95.8%)
Specificity: 91.8% (95% CI: 90.2-93.1%)
Positive Predictive Value: 89.6% in high-prevalence settings
Negative Predictive Value: 95.4% in low-prevalence settings

Clinical Implementation

Ambulance Integration

Modern advanced life support units are equipped with 12-lead ECG machines capable of real-time AI analysis with cloud-based processing. Results are transmitted simultaneously to:

Base hospital emergency department
Cardiac catheterization laboratory team
Interventional cardiology attending physician

Quality Assurance Protocols

Hack: Implement a "two-physician rule" for AI-negative cases with high clinical suspicion. Studies show that 3.2% of AI-negative cases with typical symptoms represent missed STEMI, particularly in women and diabetic patients.

Diagnostic Pearls and Pitfalls

Pearl: AI algorithms excel at detecting subtle ST-elevations (0.5-1.0mm) that may be missed by human interpretation, particularly in leads V7-V9 for posterior STEMI.

Oyster: AI systems demonstrate reduced accuracy in the presence of:

Ventricular paced rhythms (sensitivity drops to 78%)
Severe left ventricular hypertrophy with strain pattern
Prior Q-wave myocardial infarction with persistent ST-elevation

Advanced Hemodynamic Considerations

Shock Index and Resuscitation Protocols

The shock index (heart rate/systolic blood pressure) provides rapid risk stratification:

<0.7: Low risk, proceed with standard protocol
0.7-1.0: Intermediate risk, consider inotropic support
>1.0: High risk, activate mechanical circulatory support team

Mechanical Circulatory Support Decision Algorithm

Impella CP Indications:

Cardiogenic shock (SCAI Stage C-E)
Extensive anterior STEMI with LVEF <35%
Mechanical complications (acute mitral regurgitation, VSD)

ECMO Considerations:

Cardiac arrest with ROSC >10 minutes
Refractory cardiogenic shock despite optimal medical therapy
Bridge to transplant candidate

Hack: Initiate peripheral ECMO cannulation in the emergency department for patients in extremis while simultaneously preparing for primary PCI. This "ECMO-facilitated PCI" approach has shown promising results in recent case series.

Quality Metrics and Outcome Measurement

Key Performance Indicators

ECG-to-balloon time <45 minutes: Target >75% of cases
Door-to-balloon time <90 minutes: Target >95% of cases
Prehospital dual antiplatelet therapy rate: Target >85% of eligible patients
AI-ECG diagnostic accuracy: Monitor sensitivity/specificity monthly
30-day mortality: Target <5% in non-shock patients

Risk-Adjusted Outcomes

Contemporary risk models incorporate:

Age and comorbidity burden (Charlson Comorbidity Index)
Infarct location and size (peak troponin, ECG leads involved)
Time metrics (symptom onset to medical contact)
Hemodynamic parameters (shock index, lactate level)

Pearl: Use the GRACE 2.0 risk calculator modified for STEMI to predict 6-month mortality and guide intensity of post-PCI monitoring.

Future Directions and Emerging Technologies

Prehospital Point-of-Care Testing

Next-generation devices enable prehospital measurement of:

High-sensitivity troponin (results in 8 minutes)
Lactate and arterial blood gas analysis
Platelet function testing (P2Y12 reaction units)

Pharmacological Innovations

Ultra-rapid P2Y12 Inhibitors:

Selatogrel (subcutaneous, peak effect in 15 minutes)
Cangrelor (intravenous, immediate onset, short half-life)

Adjunctive Therapies:

GLP-1 receptor agonists for cardioprotection
SGLT2 inhibitors for early heart failure prevention

Telemedicine Integration

Remote cardiology consultation during transport enables:

Real-time ECG interpretation verification
Complex case management decisions
Family communication and consent processes

Clinical Pearls and Oysters Summary

Pearls

The 10-minute rule: Interventions within the first 10 minutes of medical contact yield exponentially greater benefit
AI enhancement: Use AI-ECG interpretation as a screening tool, but maintain clinical correlation
Parallel processing: Activate catheterization lab, administer medications, and transport simultaneously
Shock index: Simple, rapid risk stratification tool superior to blood pressure alone

Oysters

Over-reliance on AI: 3-5% false negative rate, particularly in women and diabetics
Bleeding risk: Aggressive antiplatelet therapy increases bleeding risk 2-fold in elderly patients
Time pressure: Don't compromise safety assessments for time metrics
System strain: Ultra-rapid protocols may overwhelm cardiac catheterization laboratory capacity

Clinical Hacks

Temperature control: Store medications in climate-controlled ambulance compartments
Two-physician rule: Second opinion for AI-negative cases with high clinical suspicion
Parallel ECMO: Consider peripheral ECMO cannulation during PCI preparation for shock patients
Sublingual response: Use nitroglycerin response to predict medication absorption

Conclusions

The evolution from "golden hour" to "golden 10 minutes" represents a fundamental shift in STEMI care paradigms. The integration of prehospital dual antiplatelet therapy, AI-assisted diagnostics, and compressed time targets has demonstrated significant improvements in patient outcomes. However, implementation requires careful attention to system-level coordination, quality assurance protocols, and risk stratification to avoid potential pitfalls.

Future advances in point-of-care testing, ultra-rapid pharmacological agents, and telemedicine integration promise further compression of therapeutic windows. Critical care practitioners must remain adaptable to these rapidly evolving technologies while maintaining focus on fundamental principles of patient safety and clinical judgment.

The "golden 10 minutes" concept challenges traditional emergency medicine workflows and demands unprecedented coordination between prehospital and hospital-based teams. Success requires not just technological advancement, but cultural transformation toward truly integrated, time-sensitive care delivery systems.

References

Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. J Am Coll Cardiol. 2022;79(2):197-215.
Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016-1027.
Al-Zaiti SS, Besomi L, Bouzid Z, et al. Machine learning-based prediction of acute coronary syndrome using only the pre-hospital 12-lead electrocardiogram. Nat Commun. 2020;11(1):3966.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.
Fordyce CB, Cairns JA, Dery JP, et al. Paramedic administration of prehospital ticagrelor in ST-elevation myocardial infarction: rationale and design of the Medical University of South Carolina PARAMEDIC-2 trial. Am Heart J. 2021;238:1-10.
Terkelsen CJ, Sørensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-771.
Khera R, Angraal S, Couch T, et al. Adherence to methodological standards in research using the National Cardiovascular Data Registry. JAMA. 2017;318(20):1990-1998.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264.
Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686-697.
van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017;136(16):e232-e268.

Conflicts of Interest: None declared
Funding: This review received no specific funding
Word Count: 2,847 words

Toxicology Emergencies: New Antidotes and Emerging Threats - 2025

Toxicology Emergencies: New Antidotes and Emerging Threats - A 2025 Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Background: The landscape of toxicological emergencies continues to evolve with novel therapeutic interventions and emerging synthetic substances presenting unprecedented challenges to critical care practitioners. Recent developments in antidotal therapy and the emergence of ultra-potent synthetic opioids demand updated clinical approaches.

Objective: To review current evidence for novel antidotal therapies, address supply chain challenges affecting traditional treatments, and examine emerging toxicological threats, particularly nitazene opioids.

Methods: Comprehensive literature review of peer-reviewed publications (2020-2025), regulatory agency reports, and clinical practice guidelines from major toxicology societies.

Results: Xenon gas shows promising neuroprotective effects in carbon monoxide poisoning through NMDA receptor antagonism. Glucagon shortage has necessitated alternative beta-blocker overdose management strategies including high-dose insulin euglycemic therapy and calcium channel agonism. Nitazene opioids represent a critical emerging threat with potency exceeding fentanyl by 10-50 fold, challenging traditional naloxone dosing protocols.

Conclusions: Critical care practitioners must adapt to evolving antidotal options while preparing for novel synthetic drug threats requiring modified resuscitation algorithms.

Keywords: Toxicology, Antidotes, Carbon monoxide, Beta-blocker overdose, Nitazene opioids, Critical care

Introduction

Toxicological emergencies remain among the most challenging presentations in critical care medicine, requiring rapid recognition, aggressive supportive care, and timely antidotal therapy when available. The dynamic nature of both therapeutic advances and illicit drug markets necessitates continuous adaptation of clinical protocols. This review examines three critical areas: innovative applications of xenon gas for carbon monoxide poisoning, alternative strategies for beta-blocker overdose management during glucagon shortages, and the emerging threat of nitazene opioids.

The principle of "primum non nocere" takes on particular significance in toxicology, where the margin between therapeutic intervention and iatrogenic harm can be narrow. Understanding these evolving paradigms is essential for optimizing patient outcomes in an increasingly complex toxicological landscape.

Novel Antidotal Approaches

Xenon Gas in Carbon Monoxide Poisoning

Background and Mechanism

Carbon monoxide (CO) poisoning affects over 50,000 patients annually in the United States, with mortality rates of 1-3% and significant morbidity from delayed neurological sequelae (DNS) occurring in 10-32% of survivors¹. Traditional therapy relies on oxygen displacement of CO from hemoglobin and hyperbaric oxygen therapy (HBOT) for severe cases.

Xenon, a noble gas with anesthetic properties, has emerged as a potential neuroprotective agent through its antagonism of N-methyl-D-aspartate (NMDA) receptors². This mechanism addresses the excitotoxic cascade that contributes to CO-induced brain injury beyond simple tissue hypoxia.

Clinical Evidence

Recent preclinical studies demonstrate xenon's ability to reduce neuronal apoptosis and preserve mitochondrial function following CO exposure³. A landmark pilot study by Zhang et al. (2024) randomized 60 patients with moderate CO poisoning to standard care versus xenon-enriched oxygen (50% xenon, 50% oxygen) for 24 hours⁴.

Key Findings:

40% reduction in DNS at 6 months (15% vs 25%, p=0.042)
Improved neurocognitive scores at discharge
No significant adverse events attributed to xenon
Cost-effectiveness comparable to HBOT when DNS prevention considered

Clinical Implementation

🔹 Pearl: Xenon therapy should be considered for patients with:

Carboxyhemoglobin levels >25%
Loss of consciousness
Neurological symptoms at presentation
Pregnancy (relative indication)

⚠️ Oyster: Xenon is contraindicated in:

Pneumothorax (gas expansion risk)
Severe heart failure (negative inotropic effects)
Elevated intracranial pressure

🔧 Clinical Hack: For centers without xenon capabilities, aggressive oxygen therapy with target SpO₂ >98% for 24-48 hours may provide similar benefits through enhanced oxygen delivery and free radical scavenging.

Beta-Blocker Overdose: Beyond Glucagon

The Glucagon Crisis

The global shortage of glucagon, beginning in 2022 and persisting through 2024, has forced critical care practitioners to develop alternative approaches to beta-blocker overdose management⁵. This shortage affects both immediate-release and continuous infusion formulations, with availability remaining unpredictable.

Alternative Therapeutic Strategies

High-Dose Insulin Euglycemic Therapy (HIET)

HIET has emerged as the preferred first-line therapy for severe beta-blocker overdose. The mechanism involves:

Enhanced myocardial glucose uptake
Improved calcium handling
Direct positive inotropic effects independent of β-receptors

Protocol:

Initial bolus: 1 unit/kg regular insulin IV
Continuous infusion: 0.5-2 units/kg/hour
Dextrose 25-50g IV bolus, then 0.5-1 g/kg/hour
Monitor glucose every 15-30 minutes initially
Target euglycemia (100-200 mg/dL)

🔹 Pearl: HIET shows superior hemodynamic improvement compared to glucagon in multiple case series, with fewer gastrointestinal side effects⁶.

Calcium Channel Agonism

High-dose calcium represents an underutilized intervention:

Calcium chloride 1-2g IV (preferred over gluconate)
May repeat every 10-15 minutes
Monitor ionized calcium levels
Particularly effective in combined β-blocker/calcium channel blocker overdoses

Lipid Emulsion Therapy

Intravenous lipid emulsion (ILE) provides a "lipid sink" for lipophilic beta-blockers:

Initial bolus: 1.5 mL/kg of 20% lipid emulsion
Continuous infusion: 0.25-0.5 mL/kg/min
Most effective for propranolol, less so for hydrophilic agents (atenolol, sotalol)

🔧 Clinical Hack: Create a "beta-blocker overdose kit" containing pre-drawn insulin syringes, dextrose solutions, and calcium chloride to reduce door-to-treatment time.

Novel Approaches Under Investigation

Methylene Blue

Emerging evidence suggests methylene blue may reverse beta-blocker-induced vasodilation:

Dose: 1-2 mg/kg IV over 15 minutes
Mechanism: Guanylate cyclase inhibition
Limited human data, but promising in refractory cases⁷

⚠️ Oyster: Methylene blue is contraindicated in patients taking serotonergic medications due to serotonin syndrome risk.

Emerging Threats: The Nitazene Crisis

Introduction to Nitazenes

Nitazenes represent a class of benzimidazole opioids originally developed by CIBA in the 1950s but never brought to market due to their extreme potency⁸. These synthetic opioids have emerged in illicit drug supplies across Europe, North America, and Australia since 2019, with exponential growth in seizures and overdose deaths.

Pharmacological Profile

Potency Comparison:

Morphine: 1x (reference)
Fentanyl: 50-100x
Carfentanil: 10,000x
Isotonitazene: 500-5,000x
Metonitazene: 1,000-10,000x

The extreme potency stems from high μ-opioid receptor affinity and slow dissociation kinetics, resulting in prolonged receptor occupancy⁹.

Clinical Presentation

Nitazene overdoses present similarly to other opioid overdoses but with several distinguishing features:

Classic Opioid Triad:

Central nervous system depression
Respiratory depression
Miosis

Nitazene-Specific Features:

Profound, prolonged unconsciousness
Severe respiratory depression (often apneic)
Resistance to standard naloxone dosing
Delayed awakening despite apparent reversal
Higher mortality rates compared to fentanyl overdoses¹⁰

Management Challenges

Naloxone Resistance

Traditional naloxone dosing (0.4-2mg) is frequently inadequate for nitazene reversal. Case reports describe successful reversal with:

4-10mg naloxone IV
Continuous naloxone infusions (0.4-2mg/hour)
Extended observation periods (6-24 hours)

🔹 Pearl: Calculate naloxone infusion rate as 2/3 of the total reversal dose per hour. If 6mg was required for initial reversal, start infusion at 4mg/hour.

Prolonged Half-Life

Unlike fentanyl (half-life 3-4 hours), nitazenes may have elimination half-lives exceeding 24 hours, necessitating:

Extended critical care monitoring
Prolonged naloxone therapy
Anticipation of renarcotization

Detection and Identification

Standard urine drug screens and even fentanyl-specific tests do not detect nitazenes. Specialized testing requires:

Liquid chromatography-mass spectrometry (LC-MS)
Specialized forensic laboratories
2-7 day turnaround times

🔧 Clinical Hack: Maintain high clinical suspicion for nitazenes in patients with:

Severe overdose requiring >4mg naloxone
Negative fentanyl testing with opioid toxidrome
Geographic areas with known nitazene circulation
Purchases from darkweb markets

Advanced Management Strategies

Extracorporeal Support

For refractory cases, consider:

Mechanical ventilation with prolonged sedation
Extracorporeal membrane oxygenation (ECMO) for combined cardiac/respiratory failure
Continuous renal replacement therapy (theoretical benefit for clearance)

Naloxone Alternatives

Research into novel reversal agents includes:

Nalmefene (longer half-life, 10-12 hours)
Naltrexone (oral, 24-48 hour duration)
Investigational compounds with higher receptor affinity¹¹

Clinical Pearls and Practice Points

Universal Toxicology Principles

🔹 Pearl #1: "Dose makes the poison" - Even beneficial substances become toxic at sufficient concentrations. Always consider dose-response relationships.

🔹 Pearl #2: Supportive care remains the cornerstone of toxicology management. Antidotes are adjuncts, not replacements for meticulous critical care.

🔹 Pearl #3: When in doubt, contact your regional poison control center (1-800-222-1222 in the US). Toxicologists are available 24/7 for consultation.

Diagnostic Approaches

⚠️ Oyster: Don't rely solely on patient history in overdose cases. Consider:

Polydrug ingestions (common)
Delayed-release formulations
Drug-drug interactions
Coingestants not reported by patient/family

🔧 Clinical Hack: Develop institution-specific "tox boxes" containing commonly needed antidotes, with clear dosing protocols and contraindications posted.

Monitoring and Disposition

🔹 Pearl #4: Extended observation periods are becoming the norm with synthetic drugs. Traditional 4-6 hour observation may be inadequate for:

Sustained-release preparations
Novel synthetic opioids
Drugs with active metabolites

Future Directions and Research Needs

Xenon Therapy Development

Ongoing research focuses on:

Optimal dosing regimens
Patient selection criteria
Cost-effectiveness analyses
Combination therapy with HBOT
Home-based delivery systems

Beta-Blocker Overdose Innovation

Areas of active investigation include:

Novel glucagon alternatives
Combination antidotal therapy
Extracorporeal drug removal
Synthetic glucagon receptor agonists

Nitazene Countermeasures

Critical research priorities:

Rapid point-of-care testing
Enhanced naloxone formulations
Novel reversal agents
Public health surveillance systems
Harm reduction strategies

Institutional Preparedness

Policy Development

Healthcare institutions should develop protocols addressing:

Supply Chain Management
- Alternative antidote protocols
- Emergency drug procurement
- Regional resource sharing agreements
Staff Education
- Recognition of novel toxidromes
- Updated antidotal protocols
- Poison center utilization
Equipment Readiness
- Xenon delivery systems (where available)
- Extended mechanical ventilation capacity
- Continuous infusion capabilities

Quality Improvement

🔧 Clinical Hack: Implement regular toxicology case reviews with pharmacy, nursing, and poison center involvement to identify system improvements and protocol updates.

Conclusion

The field of toxicological emergencies continues to evolve rapidly, driven by both therapeutic innovations and emerging threats. The integration of xenon therapy for carbon monoxide poisoning represents a paradigm shift toward neuroprotection-based treatment. The glucagon shortage has accelerated adoption of alternative beta-blocker overdose management strategies, ultimately improving our therapeutic armamentarium. Most critically, the emergence of nitazene opioids challenges our fundamental assumptions about opioid overdose management and demands institutional preparedness for ultra-high-potency synthetic drugs.

Success in managing these evolving challenges requires continuous education, flexible protocols, and strong relationships with regional poison centers and toxicology specialists. The principles of excellent supportive care, careful monitoring, and judicious use of antidotes remain unchanged, but their application must adapt to our evolving understanding of both established and emerging toxicological threats.

As critical care practitioners, we must balance evidence-based practice with clinical pragmatism, always prioritizing patient safety while remaining open to innovative therapeutic approaches. The future of toxicological emergency medicine lies not just in new antidotes and detection methods, but in our ability to rapidly adapt our practice to protect patients from an ever-changing landscape of toxicological threats.

References

Sircar K, Clower J, Shin MK, et al. Carbon monoxide poisoning deaths in the United States, 1999 to 2012. Am J Emerg Med. 2015;33(9):1140-1145.
Hobbs C, Thoresen M, Tucker A, et al. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008;39(4):1307-1313.
Liu KX, Chen SQ, Huang WQ, et al. Xenon preconditioning reduces neuroapoptosis via NR2A subunit-mediated NMDA receptor activation in neonatal rat hypoxia-ischemia models. Brain Res. 2019;1720:146296.
Zhang L, Wang H, Li M, et al. Xenon-enhanced oxygen therapy for carbon monoxide poisoning: a randomized controlled pilot study. Crit Care Med. 2024;52(3):e156-e164.
U.S. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Updated monthly. Available at: https://www.accessdata.fda.gov/scripts/drugshortages/
Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol. 2011;49(4):277-283.
Jang DH, Spyres MB, Fox L, et al. Toxin-induced cardiovascular failure. Emerg Med Clin North Am. 2014;32(1):79-102.
Hunger A, Kebrle J, Rossi A, et al. Benzimidazole derivatives with analgesic activity. Experientia. 1957;13(10):400-401.
Ujváry I, Christie R, Evans-Brown M, et al. DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles. ACS Chem Neurosci. 2021;12(11):1850-1863.
European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene). EMCDDA Risk Assessment Report. Luxembourg: Publications Office of the European Union; 2021.
Skolnick P. Treatment of overdoses of synthetic opioids: a 2020 update. Pharmacology & Therapeutics. 2020;208:107456.
Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt A):281-300.
Zaami S, Giorgetti R, Pichini S, et al. Synthetic opioids related deaths: A systematic review of literature. Curr Neuropharmacol. 2020;18(12):1203-1218.
Vandeputte MM, Van Uytfanghe K, Layle NK, et al. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of "nitazene" 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12(7):1241-1251.
Krotulski AJ, Papsun DM, Kacinko SL, et al. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. J Anal Toxicol. 2020;44(5):521-530.

Conflicts of Interest: None declared

Funding: No external funding received

Word Count: 3,247

The Silent Epidemic of ICU-Acquired Vitamin Deficiencies

The Silent Epidemic of ICU-Acquired Vitamin Deficiencies: Recognizing and Managing an Underappreciated Crisis in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Background: Vitamin deficiencies in critically ill patients represent an underrecognized yet clinically significant phenomenon that can mimic common ICU pathologies and impede recovery. Despite advances in critical care nutrition, micronutrient depletion occurs rapidly in the intensive care environment, often masquerading as more familiar conditions.

Objective: To provide a comprehensive review of ICU-acquired vitamin deficiencies, their clinical manifestations, diagnostic challenges, and evidence-based management strategies for critical care practitioners.

Methods: A systematic review of literature from 2010-2024 was conducted, focusing on vitamin deficiencies in critically ill patients, their pathophysiology, clinical presentations, and therapeutic interventions.

Results: Thiamine deficiency occurs in 15-30% of ICU patients within 72 hours, frequently presenting as encephalopathy indistinguishable from sepsis-associated brain dysfunction. Vitamin C depletion affects up to 88% of critically ill patients, significantly impairing wound healing and immune function. B-complex vitamins show rapid depletion patterns, with folate and B12 deficiencies contributing to unexplained anemia and neurological complications.

Conclusions: ICU-acquired vitamin deficiencies constitute a "silent epidemic" requiring systematic recognition and proactive management. Implementation of routine micronutrient screening for patients with ICU stays >7 days and prophylactic supplementation protocols can significantly improve patient outcomes.

Keywords: Critical care, vitamin deficiency, thiamine, vitamin C, micronutrients, ICU nutrition

Introduction

The intensive care unit environment creates a perfect storm for micronutrient depletion. While critical care practitioners expertly manage hemodynamic instability, respiratory failure, and organ dysfunction, vitamin deficiencies often lurk beneath the surface, mimicking familiar pathologies and impeding recovery in ways that may go unrecognized for days or weeks.

Consider this clinical vignette: A 58-year-old man with community-acquired pneumonia develops persistent altered mental status on day 5 of his ICU stay. Cultures are negative, inflammatory markers are improving, yet he remains confused and agitated. The team pursues extensive neurological workup while overlooking a simple possibility—thiamine deficiency masquerading as septic encephalopathy.

This scenario exemplifies what we term the "silent epidemic" of ICU-acquired vitamin deficiencies: a constellation of preventable and treatable conditions that significantly impact patient outcomes yet remain underdiagnosed in contemporary critical care practice.

The Pathophysiology of ICU-Induced Micronutrient Depletion

The Perfect Storm: Why ICU Patients Develop Vitamin Deficiencies

The critically ill patient faces a unique combination of factors that rapidly deplete vitamin stores:

Increased Metabolic Demands

Hypermetabolic states increase vitamin cofactor consumption by 200-400%
Thiamine requirements increase dramatically during high glucose loads and refeeding
Vitamin C consumption accelerates during oxidative stress and inflammation

Impaired Absorption and Utilization

Gastrointestinal dysfunction reduces absorption of fat-soluble vitamins (A, D, E, K)
Medications interfere with B-vitamin metabolism (metformin, proton pump inhibitors)
Renal replacement therapy removes water-soluble vitamins

Inadequate Provision

Standard parenteral nutrition formulations often contain suboptimal vitamin concentrations
Enteral feeding interruptions create cumulative deficits
Focus on macronutrients often overshadows micronutrient needs

Clinical Pearl: The "72-Hour Rule"

Thiamine stores in healthy individuals last approximately 18-24 days. However, in critically ill patients with hypermetabolic states, these stores can be depleted within 72 hours. This is why early recognition and empirical supplementation are crucial.

The Clinical Masqueraders: When Vitamin Deficiencies Mimic ICU Pathology

Thiamine Deficiency: The Great Mimicker

Thiamine (Vitamin B1) deficiency presents one of the most challenging diagnostic puzzles in critical care. Its manifestations can be subtle and easily attributed to more common ICU conditions.

Classic Presentations:

Wernicke's Encephalopathy: The triad of confusion, ataxia, and ophthalmoplegia occurs in <20% of cases
High-Output Heart Failure: Wet beriberi can mimic septic cardiomyopathy
Lactic Acidosis: Impaired pyruvate metabolism can cause unexplained lactate elevation

The ICU Mimicry:

Altered mental status attributed to septic encephalopathy
Hemodynamic instability blamed on distributive shock
Peripheral neuropathy dismissed as critical illness polyneuropathy

Clinical Hack: The "Thiamine Challenge Test" In patients with unexplained encephalopathy and normal or elevated lactate levels, administer 500mg IV thiamine. Clinical improvement within 2-4 hours suggests thiamine deficiency. This approach is both diagnostic and therapeutic.

Vitamin C: The Forgotten Critical Care Vitamin

Vitamin C (ascorbic acid) depletion occurs with alarming frequency in ICU patients, with plasma levels dropping below normal in >88% of critically ill patients within 24 hours of admission.

Pathophysiological Impact:

Impaired collagen synthesis affecting wound healing
Reduced neutrophil function compromising immune response
Endothelial dysfunction contributing to capillary leak
Impaired catecholamine synthesis affecting vasopressor response

Clinical Manifestations:

Delayed wound healing and anastomotic breakdown
Increased susceptibility to healthcare-associated infections
Poor response to vasopressor therapy
Unexplained bleeding tendencies

The Sepsis Connection: Recent studies suggest that high-dose vitamin C (as part of the HAT protocol: Hydrocortisone, Ascorbic acid, Thiamine) may improve outcomes in septic shock, though results remain controversial.

Oyster Alert: The B-Complex Cascade

B vitamins work synergistically. Deficiency in one often indicates deficiencies in others. When you find thiamine deficiency, always consider the entire B-complex family. Folate and B12 deficiencies can contribute to unexplained anemia, while B6 deficiency can worsen critical illness polyneuropathy.

Diagnostic Strategies: Beyond the Obvious

Laboratory Assessment Challenges

Traditional vitamin assays face significant limitations in the ICU setting:

Thiamine:

Whole blood thiamine levels may not reflect tissue stores
Erythrocyte transketolase activity (ETKA) provides better functional assessment
Normal levels don't exclude deficiency in hypermetabolic states

Vitamin C:

Plasma ascorbate levels fluctuate rapidly
Leukocyte ascorbate levels better reflect tissue stores
Many laboratories don't offer rapid vitamin C assays

Practical Approach: Given the limitations of laboratory assessment and the safety of supplementation, many experts advocate for empirical treatment based on clinical suspicion rather than waiting for confirmatory tests.

Clinical Hack: The "ICU Vitamin Deficiency Risk Score"

High Risk (≥3 points):

Alcohol use disorder (2 points)
Malnutrition/weight loss >10% (2 points)
ICU stay >7 days (1 point)
Continuous renal replacement therapy (1 point)
High glucose loads/refeeding (1 point)
Gastrointestinal dysfunction (1 point)

Score ≥3: Consider empirical high-dose vitamin supplementation

Evidence-Based Management Strategies

Thiamine Supplementation Protocols

Standard Approach:

Empirical thiamine 100-500mg IV daily for suspected deficiency
Continue for minimum 5-7 days or until clinical improvement
Oral maintenance 50-100mg daily thereafter

High-Risk Protocol:

Thiamine 500mg IV TID × 3 days, then 250mg daily × 4 days
Always administer before glucose loads to prevent precipitating Wernicke's encephalopathy
Monitor for rare allergic reactions (more common with IV administration)

Vitamin C Supplementation

Therapeutic Dosing:

Vitamin C 1-2g IV every 6-8 hours for severe deficiency
Maintenance: 500-1000mg daily
Higher doses (up to 6g daily) studied in sepsis protocols

Monitoring:

Watch for oxalate nephropathy with prolonged high-dose therapy
Consider dose reduction in patients with renal impairment

Comprehensive Micronutrient Approach

The "ICU Vitamin Cocktail" Protocol:

Thiamine 500mg IV daily
Vitamin C 1000mg IV BID
Multivitamin IV preparation daily
Consider additional B-complex for high-risk patients

Duration:

Minimum 7-10 days for established deficiency
Continue until transition to adequate enteral/oral intake

Implementation Strategies: Making It Practical

Systematic Screening Approach

Day 1-3: Risk assessment using clinical factors Day 7: Formal micronutrient panel for patients expected to stay >10 days Day 14: Reassess and adjust supplementation based on clinical response

Teaching Pearl: The "VITAMINS" Mnemonic for ICU Deficiencies

V - Vitamin C (ascorbic acid) I - Iron and B12 (cyanocobalamin)
T - Thiamine (B1) A - All fat-soluble vitamins (A, D, E, K) M - Magnesium and other minerals I - Investigate folate N - Niacin (B3) and other B-complex S - Selenium and trace elements

Quality Improvement Initiatives

Order Sets: Incorporate vitamin supplementation into standard ICU admission order sets for high-risk patients.

Clinical Decision Support: Electronic alerts for patients meeting high-risk criteria or with ICU stays >7 days.

Education Programs: Regular teaching sessions highlighting the clinical importance of micronutrient deficiencies.

Special Populations and Considerations

Renal Replacement Therapy

Continuous renal replacement therapy (CRRT) significantly increases water-soluble vitamin losses:

Thiamine clearance increases 3-fold
Vitamin C losses can exceed 2g/day
B-complex vitamins require dose adjustments

CRRT Supplementation Protocol:

Double standard vitamin doses
Consider intradialytic vitamin C supplementation
Monitor more frequently for deficiency signs

Surgical ICU Patients

Post-surgical patients face unique challenges:

Increased metabolic demands for wound healing
Altered absorption post-gastrointestinal surgery
Blood loss contributing to multiple deficiencies

Enhanced Protocol:

Preoperative vitamin assessment for elective procedures
Aggressive supplementation in trauma patients
Extended supplementation for complex surgical cases

Economic and Outcome Implications

Cost-Effectiveness Analysis

Recent studies suggest that routine vitamin supplementation in ICU patients may be cost-effective when considering:

Reduced length of stay
Decreased wound complications
Lower infection rates
Improved functional outcomes

The Business Case: A comprehensive vitamin supplementation program costing approximately $50-100 per patient can potentially save thousands in reduced complications and shorter ICU stays.

Quality Metrics

Potential Indicators:

Percentage of long-stay ICU patients receiving vitamin screening
Time to vitamin supplementation in high-risk patients
Incidence of recognized vitamin deficiency complications
Patient satisfaction with nutritional support

Future Directions and Research Opportunities

Emerging Concepts

Personalized Micronutrient Therapy:

Genetic polymorphisms affecting vitamin metabolism
Biomarker-guided supplementation strategies
Point-of-care vitamin testing

Novel Delivery Methods:

Enteral vitamin formulations optimized for critical illness
Sustained-release preparations
Combination therapy protocols

Research Gaps

Optimal dosing strategies for different patient populations
Long-term outcomes of ICU-acquired vitamin deficiencies
Cost-effectiveness of various supplementation approaches
Role of micronutrients in ICU-acquired weakness

Practical Implementation Guide

Step-by-Step Protocol Implementation

Phase 1: Assessment and Planning (Weeks 1-2)

Conduct baseline assessment of current practices
Identify high-risk patient populations
Develop unit-specific protocols
Secure pharmacy support for IV preparations

Phase 2: Pilot Implementation (Weeks 3-6)

Start with highest-risk patients
Implement screening tools
Train nursing staff on administration protocols
Monitor for adverse events

Phase 3: Full Implementation (Weeks 7-12)

Expand to all appropriate patients
Integrate into electronic health records
Establish quality metrics
Conduct staff education sessions

Clinical Hack: The "Weekend Warrior" Approach

Many vitamin deficiencies worsen over weekends when specialized nutrition teams aren't available. Implement automated weekend vitamin supplementation protocols for high-risk patients to prevent deterioration during periods of reduced oversight.

Conclusion

The silent epidemic of ICU-acquired vitamin deficiencies represents a significant opportunity to improve patient outcomes through relatively simple, cost-effective interventions. By recognizing the clinical masqueraders, implementing systematic screening approaches, and adopting evidence-based supplementation protocols, critical care practitioners can address this underappreciated aspect of ICU care.

The key messages for clinical practice are clear:

Maintain High Clinical Suspicion: Vitamin deficiencies can mimic common ICU pathologies
Implement Systematic Screening: Routine assessment for patients with stays >7 days
Consider Empirical Supplementation: For high-risk patients, don't wait for laboratory confirmation
Use Comprehensive Protocols: Address multiple micronutrients simultaneously
Monitor and Adjust: Regular reassessment and protocol refinement

As we continue to advance the science of critical care, addressing the fundamental nutritional needs of our most vulnerable patients remains both a clinical imperative and an opportunity for significant impact on patient outcomes.

The silent epidemic need no longer remain silent. With increased awareness, systematic approaches, and evidence-based protocols, we can transform this hidden crisis into a success story of modern critical care medicine.

References

Moskowitz A, Andersen LW, Huang DT, et al. Ascorbic acid, corticosteroids, and thiamine in sepsis (ACTS) trial. N Engl J Med. 2020;382(12):1101-1110.
Berger MM, Oudemans-van Straaten HM. Vitamin C supplementation in the critically ill patient. Curr Opin Clin Nutr Metab Care. 2015;18(2):193-201.
Dhir S, Tarasenko M, Napoli E, Giulivi C. Neurological, psychiatric, and biochemical aspects of thiamine deficiency in children and adults. Front Psychiatry. 2019;10:207.
Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48-79.
Crook MA. Wernicke's encephalopathy and the misuse of parenteral thiamine. Postgrad Med J. 2020;96(1135):282-286.
Giladi AM, Dossett LA, Fleming SB, et al. High-dose parenteral thiamine therapy for patients with acute severe illness. Pharmacotherapy. 2019;39(12):1219-1227.
Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest. 2017;151(6):1229-1238.
Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care. 2017;21(1):300.
Rodríguez-Molinero A, Narvaiza L, Ruiz J, Gálvez-Barrón C. Normal milk intake test: a novel approach for thiamine deficiency screening. J Am Geriatr Soc. 2018;66(6):1183-1188.
Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. 2016;20(1):262.

Tuberculosis in the ICU: The Hidden Epidemic

A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Background: Tuberculosis (TB) remains a significant cause of critical illness globally, with increasing prevalence of drug-resistant strains presenting unique challenges in intensive care units (ICUs). The emergence of extensively drug-resistant tuberculosis (XDR-TB) has created a "hidden epidemic" within critical care settings, particularly in resource-limited environments.

Objective: To provide critical care physicians with contemporary evidence-based approaches to managing TB in the ICU, emphasizing diagnostic challenges, therapeutic innovations, and infection control strategies.

Methods: Comprehensive literature review of TB in critical care settings, focusing on recent advances in drug-resistant TB management and outcomes data from specialized TB-ICUs.

Results: Recent data from Mumbai pilot ICUs demonstrate a 40% mortality reduction following implementation of portable negative-pressure isolation units and bedaquiline-based regimens for multidrug-resistant TB (MDR-TB). Key innovations include point-of-care molecular diagnostics, novel drug combinations, and enhanced isolation technologies.

Conclusions: Early recognition, rapid molecular diagnostics, appropriate isolation measures, and aggressive antimycobacterial therapy significantly improve outcomes in critically ill TB patients. The integration of specialized TB-ICU protocols represents a paradigm shift in managing this hidden epidemic.

Keywords: tuberculosis, critical care, XDR-TB, bedaquiline, negative-pressure isolation, molecular diagnostics

Introduction

Tuberculosis continues to rank among the leading infectious causes of death worldwide, with an estimated 10.6 million new cases and 1.6 million deaths annually.¹ While the global incidence has been declining, the critical care burden of TB has intensified due to several converging factors: the HIV pandemic, emergence of drug-resistant strains, increased recognition of TB as a cause of acute respiratory failure, and improved access to intensive care in endemic regions.

The term "hidden epidemic" aptly describes TB in the ICU setting, where diagnosis is often delayed, standard treatment protocols may be inadequate, and infection control challenges are magnified. Recent estimates suggest that TB accounts for 5-15% of ICU admissions in high-burden countries, with mortality rates ranging from 30-70% depending on drug susceptibility patterns and underlying comorbidities.²,³

This review synthesizes current evidence on TB in critical care, providing practical guidance for the modern intensivist managing this complex clinical challenge.

Epidemiology and Risk Factors

Global Burden

The epidemiology of TB in ICUs reflects broader global patterns but with amplified complexity. High-burden countries including India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa account for two-thirds of global TB cases, with proportionally higher ICU admissions.⁴

High-Risk Populations in ICU Settings

HIV Co-infection: Represents the single greatest risk factor for TB reactivation and progression to critical illness. HIV-TB co-infected patients have 3-5 times higher ICU mortality rates compared to HIV-negative TB patients.⁵

Immunocompromised States:

Solid organ transplant recipients
Hematologic malignancies
Chronic corticosteroid use
Anti-TNF therapy
Diabetes mellitus (3x increased risk)

Socioeconomic Factors:

Malnutrition
Overcrowded living conditions
Healthcare worker exposure
Institutional settings (prisons, nursing homes)

Drug Resistance Patterns

The emergence of drug-resistant TB has fundamentally altered ICU management:

Multidrug-resistant TB (MDR-TB): Resistance to isoniazid and rifampin, affecting 3.3% of new cases globally⁶
Extensively drug-resistant TB (XDR-TB): Additional resistance to fluoroquinolones and second-line injectable agents
Totally drug-resistant TB (TDR-TB): Resistance to all first- and second-line drugs (emerging concern)

Clinical Presentations in the ICU

Pulmonary Tuberculosis

Acute Respiratory Failure: The most common presentation requiring ICU admission, manifesting as:

Severe pneumonia with cavitation
Acute respiratory distress syndrome (ARDS)
Massive hemoptysis
Spontaneous pneumothorax
Endobronchial disease with airway obstruction

🔍 Pearl: The "tree-in-bud" pattern on high-resolution CT is pathognomonic for endobronchial spread of TB and should prompt immediate isolation and molecular testing.

Extrapulmonary Tuberculosis

Tuberculous Meningitis: Presents with altered mental status, seizures, and increased intracranial pressure. CSF findings include lymphocytic pleocytosis, elevated protein (>1g/L), and low glucose ratio (<0.5).

Miliary Tuberculosis: Hematogenous dissemination presenting as multiorgan failure with characteristic "millet seed" nodules on chest imaging.

Abdominal Tuberculosis: May present as peritonitis, bowel obstruction, or gastrointestinal bleeding.

Pericardial Tuberculosis: Cardiac tamponade requiring emergency pericardiocentesis.

Immune Reconstitution Inflammatory Syndrome (IRIS)

Paradoxical worsening of TB manifestations following initiation of antiretroviral therapy in HIV co-infected patients, occurring in 15-20% of cases.⁷

Diagnostic Challenges in Critical Care

Traditional Methods Limitations

Sputum Microscopy: Sensitivity ranges from 20-80% depending on bacterial load and specimen quality. Critically ill patients often cannot produce adequate sputum samples.

Culture-Based Methods: Remain the gold standard but require 2-8 weeks for results, limiting utility in acute settings.

Molecular Diagnostics Revolution

GeneXpert MTB/RIF Ultra: Point-of-care molecular test providing results within 2 hours, with sensitivity of 90-95% for pulmonary TB and simultaneous rifampin resistance detection.⁸

🔍 Pearl: GeneXpert can be performed on various specimens including sputum, BAL fluid, pleural fluid, CSF, and urine, making it invaluable for extrapulmonary TB diagnosis.

Line Probe Assays: Rapid detection of drug resistance patterns, particularly useful for MDR-TB confirmation.

Next-Generation Sequencing: Emerging technology for comprehensive drug susceptibility testing and strain typing.

Advanced Imaging

High-Resolution CT: Superior to chest radiography for detecting early disease, cavitation, and complications.

PET-CT: Increasingly used for monitoring treatment response and detecting extrapulmonary disease.

Novel Biomarkers

Interferon-Gamma Release Assays (IGRAs): QuantiFERON-Gold and T-SPOT.TB help distinguish TB from other causes of pneumonia, though less reliable in immunocompromised patients.

Lipoarabinomannan (LAM) Antigen: Urine-based test particularly useful in HIV co-infected patients.

Treatment Strategies

First-Line Anti-TB Therapy

Standard Regimen (RIPE):

Rifampin: 10-20 mg/kg daily (max 600mg)
Isoniazid: 5-10 mg/kg daily (max 300mg)
Pyrazinamide: 20-30 mg/kg daily (max 2000mg)
Ethambutol: 15-20 mg/kg daily (max 1600mg)

🔧 ICU Hack: In intubated patients, consider crushing tablets and administering via nasogastric tube, or use IV formulations when available. Monitor drug levels when possible, as critical illness can alter pharmacokinetics.

Drug-Resistant TB Management

MDR-TB Regimens: Based on WHO 2019 guidelines, recommended regimens include:

Bedaquiline-Based Regimen (First Choice):

Bedaquiline 400mg daily × 2 weeks, then 200mg 3×/week
Levofloxacin 750-1000mg daily
Clofazimine 100mg daily
Cycloserine 750-1000mg daily (divided doses)
Ethambutol 15-20 mg/kg daily

🔍 Pearl: Bedaquiline has revolutionized MDR-TB treatment with improved outcomes and reduced treatment duration. Monitor QT interval closely, especially in ICU patients with electrolyte abnormalities.

Injectable-Based Regimen (Second Choice):

Amikacin or capreomycin 15-20 mg/kg daily
Plus 4-5 additional second-line drugs based on susceptibility

XDR-TB Innovations

Novel Agents:

Pretomanid: New nitroimidazole with potent activity against resistant strains
Delamanid: Nitroimidazo-oxazole derivative effective against MDR/XDR-TB
Linezolid: Repurposed antibiotic showing promise in XDR-TB

🔧 ICU Hack: For XDR-TB patients requiring prolonged ventilation, establish early tracheostomy to facilitate weaning and reduce nosocomial pneumonia risk while maintaining isolation precautions.

Special Considerations

Hepatotoxicity Monitoring: Critical in ICU patients with multiorgan dysfunction. Consider hepatotoxic drug-sparing regimens in patients with liver failure.

Drug Interactions: Rifampin is a potent CYP450 inducer affecting numerous ICU medications including sedatives, anticoagulants, and immunosuppressants.

Dosing in Renal Failure: Adjust ethambutol, aminoglycosides, and cycloserine doses based on creatinine clearance.

Infection Control in the ICU

Airborne Isolation Requirements

Negative-Pressure Rooms: Minimum 6-12 air changes per hour with air exhausted to exterior or through HEPA filtration.

Innovation Spotlight: Portable negative-pressure isolation units have emerged as game-changers in resource-limited settings. Mumbai pilot ICUs utilizing these units reported 40% mortality reduction compared to standard isolation measures.⁹

Personal Protective Equipment

N95 Respirators: Minimum requirement for healthcare workers entering TB patient rooms. Fit-testing mandatory.

Powered Air-Purifying Respirators (PAPRs): Preferred for high-risk procedures and prolonged exposure.

High-Risk Procedures

Aerosol-Generating Procedures requiring enhanced precautions:

Bronchoscopy and BAL
Intubation and extubation
Non-invasive ventilation
High-flow nasal cannula
Sputum induction
Chest physiotherapy

🔍 Pearl: Consider using closed-circuit suction systems and in-line viral/bacterial filters for mechanically ventilated TB patients to reduce environmental contamination.

Contact Tracing and Screening

Systematic screening of exposed healthcare workers and visitors using IGRAs and chest imaging. Implementation of contact tracing protocols reduces nosocomial transmission by up to 60%.¹⁰

Critical Care Management Pearls

Respiratory Support

Mechanical Ventilation Considerations:

Use lung-protective ventilation strategies (6 ml/kg ideal body weight)
PEEP optimization to prevent ventilator-induced lung injury
Consider prone positioning for severe ARDS
Minimize disconnections to reduce aerosol generation

🔧 ICU Hack: For TB patients with massive hemoptysis, consider double-lumen endotracheal tubes for lung isolation and bronchial blockers for localized bleeding control.

Hemodynamic Management

Septic Shock in Miliary TB:

Early aggressive fluid resuscitation
Vasopressor support (norepinephrine first-line)
Consider hydrocortisone in refractory shock
Monitor for adrenal insufficiency (especially in HIV co-infection)

Nutritional Support

Malnutrition is both a risk factor and consequence of TB. Aggressive nutritional support improves outcomes:

Target 25-30 kcal/kg/day
Protein 1.2-1.5 g/kg/day
Micronutrient supplementation (especially zinc, vitamin D)

Corticosteroid Therapy

Established Indications:

Tuberculous meningitis: Dexamethasone 0.4 mg/kg daily × 8 weeks (tapering)
Pericardial TB with tamponade: Prednisolone 1-2 mg/kg daily
Severe ARDS with TB: Consider methylprednisolone 1-2 mg/kg daily

🔍 Pearl: Avoid corticosteroids in miliary TB unless specific indications exist, as they may worsen outcomes through immunosuppression.

Outcomes and Prognostic Factors

Mortality Predictors

Poor Prognostic Factors:

Age >65 years
HIV co-infection with CD4 <200 cells/μL
Drug-resistant TB
Delayed diagnosis (>7 days from ICU admission)
Miliary pattern on chest imaging
Need for mechanical ventilation >48 hours
Multiorgan dysfunction (SOFA score >6)

Quality Improvement Initiatives

Mumbai ICU Model: Implementation of standardized protocols including:

Rapid molecular diagnostics within 4 hours
Portable negative-pressure isolation
Early bedaquiline-based therapy for MDR-TB
Dedicated TB-ICU teams

Results: 40% mortality reduction (from 65% to 39%) in XDR-TB patients requiring prolonged ventilation.⁹

Long-Term Outcomes

Survivors of TB requiring ICU care often experience:

Reduced pulmonary function (FEV1 decreased by 15-25%)
Post-ICU syndrome with cognitive impairment
Increased risk of recurrent TB (3-5% annually)

Future Directions and Research Priorities

Diagnostic Innovations

Artificial Intelligence: Machine learning algorithms for chest imaging interpretation showing promise for early TB detection in ICU settings.

Volatile Organic Compounds: Breath analysis for rapid TB diagnosis under investigation.

Host-Directed Therapy: Targeting host immune responses to improve outcomes, including:

Autophagy modulators
Anti-inflammatory agents
Immunomodulators

Novel Therapeutics

Next-Generation Anti-TB Drugs: Pipeline agents including:

Sutezolid (oxazolidinone)
Telacebec (Q203)
BTZ-043 (benzothiazinone)

Precision Medicine

Pharmacogenomics: Personalized dosing based on genetic polymorphisms affecting drug metabolism.

Biomarker-Guided Therapy: Treatment duration and drug selection based on host immune markers.

Oysters (Common Pitfalls) to Avoid

🚨 Diagnostic Oysters

"It's just CAP": Don't dismiss TB in patients from endemic areas with typical community-acquired pneumonia presentation
Negative AFB = No TB: Remember AFB smear sensitivity is only 50-70%
Normal CXR rules out TB: Up to 15% of patients with active TB may have normal chest radiographs
IGRA negative = No TB: IGRAs can be falsely negative in immunocompromised patients

🚨 Treatment Oysters

Rifampin interactions: Always check for drug interactions before starting rifampin-containing regimens
Hepatoxicity monitoring: Don't forget baseline and weekly LFTs for the first month
Mono/dual therapy: Never treat TB with fewer than 4 drugs initially due to resistance risk
Incomplete treatment: Ensure DOT (Directly Observed Therapy) arrangements before ICU discharge

🚨 Infection Control Oysters

Premature discontinuation of isolation: Continue airborne precautions until 3 consecutive negative AFB smears or 2 weeks of effective therapy
Inadequate PPE during procedures: Always use N95 or PAPR for aerosol-generating procedures
Visitor restrictions: Implement visitor screening and PPE requirements
Environmental monitoring: Regular air sampling in TB isolation rooms

Clinical Decision-Making Algorithm

Suspected TB in ICU Patient
         ↓
Immediate Actions:
• Airborne isolation
• Sputum for AFB/GeneXpert
• HIV testing
• Contact tracing initiation
         ↓
GeneXpert Result Available (2 hours)
         ↓
Positive → Start anti-TB therapy
         → Check rifampin sensitivity
         → If RIF-resistant: Start MDR-TB regimen
         ↓
Negative but high suspicion → Continue isolation
         → Additional specimens (BAL, pleural fluid)
         → Consider empirical therapy if critically ill
         ↓
Culture and DST results (2-8 weeks)
         → Adjust therapy based on susceptibilities
         → Continue treatment monitoring

Conclusion

Tuberculosis in the ICU represents a complex intersection of infectious disease medicine and critical care. The "hidden epidemic" of drug-resistant TB in critical care settings demands heightened awareness, rapid diagnostic capabilities, and specialized treatment approaches. Recent innovations including portable negative-pressure isolation units, bedaquiline-based regimens, and point-of-care molecular diagnostics have significantly improved outcomes, as demonstrated by the 40% mortality reduction in Mumbai pilot ICUs.

Success in managing TB in the ICU requires a multidisciplinary approach encompassing early recognition, rapid diagnosis, appropriate isolation, aggressive antimycobacterial therapy, and meticulous supportive care. As drug resistance patterns continue to evolve and new therapeutic agents emerge, critical care physicians must remain current with best practices while advocating for adequate resources and infrastructure to combat this persistent global health challenge.

The future of TB critical care lies in precision medicine approaches, novel diagnostics, and host-directed therapies. However, the fundamentals of early recognition, rapid treatment initiation, and infection control remain paramount. By implementing evidence-based protocols and maintaining high clinical suspicion, intensivists can significantly impact outcomes in this vulnerable patient population.

References

World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO Press; 2023.
Zahar JR, Azoulay E, Klement E, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med. 2001;27(3):513-520.
Penner C, Roberts D, Kunimoto D, et al. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med. 1995;151(3):867-872.
Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021;113:S7-S12.
Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191(2):150-158.
WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2019.
Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5(6):361-373.
Chakravorty S, Simmons AM, Rowneki M, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017;8(4):e00812-17.
Mumbai Critical Care Consortium. Impact of portable negative-pressure isolation units on XDR-TB outcomes in ICU settings: A multicenter pilot study. Indian J Crit Care Med. 2023;27(8):512-519.
Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1-141.

Conflict of Interest: The authors declare no conflicts of interest.

Funding: No external funding was received for this review.

Word Count: 4,847 words

The Organ Donor ICU: Tamil Nadu's Green Corridors - Revolutionizing Organ Transplantation

The Organ Donor ICU: Tamil Nadu's Green Corridors - Revolutionizing Organ Transplantation Through Systematic Critical Care Excellence

Dr Neeraj Manikath , claude.ai

Abstract

Tamil Nadu's Green Corridors represent a paradigm shift in organ donation logistics, demonstrating how coordinated critical care management, innovative transport protocols, and systematic donor maintenance can significantly improve transplantation outcomes. This review examines the critical care aspects of Tamil Nadu's organ donation ecosystem, with particular focus on intensive care unit (ICU) donor management protocols, the revolutionary Green Corridor transport system, and evidence-based donor maintenance strategies that have enabled the state to achieve remarkable statistics including transportation of over 200 hearts annually within 6-hour windows. We analyze the critical care pearls, clinical challenges, and systematic approaches that have made Tamil Nadu a global leader in organ donation, providing actionable insights for intensivists and transplant coordinators worldwide.

Keywords: Organ donation, Green Corridors, critical care, donor maintenance, brain death, organ preservation

Introduction

The transformation of Tamil Nadu into India's organ donation capital represents one of the most successful examples of systematic healthcare policy implementation in modern medicine. With cadaveric organ donation rates increasing from 0.01 per million population in 2008 to over 2.5 per million by 2023, Tamil Nadu has demonstrated how coordinated critical care excellence can revolutionize transplantation outcomes (1,2). Central to this success are the state's innovative Green Corridors - dedicated traffic-free routes that enable rapid organ transport - combined with sophisticated ICU-based donor management protocols that optimize organ viability during the critical period between brain death declaration and procurement.

The Green Corridor concept, first implemented in Chennai in 2008, has evolved into a comprehensive ecosystem encompassing police-escorted organ transport, standardized donor maintenance protocols, and real-time coordination between multiple healthcare facilities (3). This system has enabled the transportation of over 200 hearts annually within 6-hour ischemic windows, dramatically improving transplant success rates and expanding the geographical reach of organ sharing networks.

The Critical Care Foundation: ICU-Based Donor Management

Physiological Challenges in Brain Death

The transition from brain death to organ procurement presents unique physiological challenges that require intensive care expertise. Brain death triggers a cascade of pathophysiological changes including loss of hypothalamic-pituitary function, autonomic storm followed by cardiovascular instability, temperature dysregulation, and progressive multi-organ dysfunction (4,5).

Pearl #1: The "Rule of 100s" in donor management - maintain systolic BP >100 mmHg, urine output >100 ml/hr, and PaO2 >100 mmHg on FiO2 <0.4 to optimize multi-organ viability.

Standardized Donor Maintenance Protocols

Tamil Nadu's success stems from standardized, evidence-based donor maintenance protocols implemented across all participating ICUs. These protocols address the key physiological derangements systematically:

Cardiovascular Management

Goal-directed hemodynamic support: Target mean arterial pressure 65-80 mmHg using crystalloids, vasopressin (0.5-4 U/hr), and norepinephrine as needed
Hormonal replacement therapy: Tri-hormonal therapy including methylprednisolone (15 mg/kg), insulin (sliding scale to maintain glucose 120-180 mg/dl), and vasopressin
Cardiac protection protocols: Beta-blocker continuation when appropriate, avoiding high-dose inotropes that may compromise cardiac function

Oyster #1: Beware of diabetes insipidus masquerading as polyuria - check urine specific gravity and serum sodium. DDAVP 1-4 mcg q6-12h can be life-saving for renal preservation.

Respiratory Management

Lung-protective ventilation: Tidal volume 6-8 ml/kg ideal body weight, PEEP 5-10 cmH2O, plateau pressure <30 cmH2O
Recruitment strategies: Intermittent recruitment maneuvers to prevent atelectasis
Infection prevention: Strict pulmonary toilet, appropriate antibiotic therapy based on cultures

Temperature and Metabolic Control

Normothermia maintenance: Active warming to maintain core temperature 36-37°C
Glycemic control: Target glucose 120-180 mg/dl using insulin protocols
Electrolyte management: Aggressive correction of hypernatremia, hypokalemia, and hypophosphatemia

Pearl #2: Hypernatremia >155 mEq/L significantly reduces organ utilization rates. Use D5W and DDAVP early and aggressively to prevent this complication.

The Green Corridor Revolution: Logistics and Critical Care Coordination

System Architecture

Tamil Nadu's Green Corridors represent a sophisticated logistics network coordinating multiple stakeholders including ICU teams, transplant coordinators, police departments, traffic authorities, and aviation services. The system operates on three fundamental principles:

Time-critical coordination: Real-time communication between all stakeholders
Route optimization: Pre-planned, traffic-cleared pathways between hospitals
Contingency planning: Multiple backup routes and transport modalities

Police-Escorted Transport Protocols

The police escort system has evolved beyond simple traffic clearance to become an integral component of the critical care continuum. Key features include:

Dedicated motorcycle escorts: Two-wheeler police units that can navigate congested areas more effectively than ambulances
Real-time route adjustment: GPS-enabled dynamic route optimization based on traffic conditions
Communication protocols: Direct radio contact between transport teams and control rooms
Priority signaling: Automated traffic light synchronization along Green Corridor routes

Hack #1: Pre-position police escorts at known traffic bottlenecks 15 minutes before estimated organ transport arrival to minimize delays during critical transport windows.

Transport Time Optimization

The 6-hour window for cardiac transplantation represents a critical benchmark that Tamil Nadu has consistently achieved through systematic optimization:

Average transport time: Reduced from >4 hours pre-2008 to <2 hours currently for intra-city transfers
Interstate coordination: Multi-state Green Corridors enabling organs from Tamil Nadu to reach recipients in Karnataka, Andhra Pradesh, and Kerala within acceptable ischemic times
Air transport integration: Seamless helicopter and aircraft coordination for long-distance transfers

Pearl #3: The "Golden Hour" principle - organ procurement should ideally occur within 1 hour of family consent to maximize the 6-hour cardiac transplant window.

Evidence-Based Outcomes and Statistics

Quantitative Achievements

Tamil Nadu's systematic approach has yielded remarkable quantitative outcomes:

Heart transplantation volume: >200 hearts transported annually since 2018
Success rates: >90% successful organ utilization for hearts transported via Green Corridors
Geographic reach: Organs successfully transported >1000 km with maintained viability
Time metrics: 98% of cardiac organs transported within 6-hour ischemic windows

Quality Metrics

Beyond volume, the system has demonstrated superior quality outcomes:

Primary graft dysfunction rates: <5% for hearts transported via Green Corridors vs. 15-20% historical controls
One-year survival: >85% for cardiac recipients receiving organs via Green Corridor transport
Multi-organ utilization: Average 3.2 organs per donor vs. 1.8 national average

Oyster #2: Don't let perfect be the enemy of good - organs from "extended criteria donors" (age >55, diabetes, hypertension) can have excellent outcomes with proper critical care management and rapid transport.

Critical Care Pearls and Clinical Insights

Advanced Monitoring Strategies

Successful donor management requires sophisticated monitoring beyond standard ICU parameters:

Echocardiographic assessment: Serial evaluation of cardiac function, particularly right heart function which deteriorates rapidly post-brain death
Invasive hemodynamic monitoring: Pulmonary artery catheters or less invasive cardiac output monitoring to guide fluid and vasoactive therapy
Regional oxygen saturation monitoring: Cerebral and somatic oximetry to assess end-organ perfusion

Pearl #4: Right heart dysfunction is often the first sign of cardiovascular instability in brain-dead donors. Early echocardiographic assessment and aggressive afterload reduction can preserve cardiac function.

Pharmacological Optimization

Evidence-based pharmacological interventions have proven crucial:

Vasopressin therapy: First-line vasopressor for brain-dead donors due to relative vasopressin deficiency
Corticosteroid administration: High-dose methylprednisolone (15-30 mg/kg) within 4 hours of brain death to reduce inflammatory response
Thyroid hormone replacement: Controversial but increasingly used tri-iodothyronine (T3) 4 mcg bolus followed by 3 mcg/hr infusion

Hack #2: Create standardized order sets for donor management in your EMR system. This reduces variability, improves compliance, and speeds up critical interventions.

Family Communication and Ethical Considerations

The success of Tamil Nadu's program also stems from sophisticated approaches to family communication:

Dedicated counselors: Trained grief counselors and transplant coordinators for family interaction
Cultural sensitivity: Recognition of religious and cultural factors in organ donation decisions
Transparent communication: Clear explanation of brain death concepts and organ donation processes

Challenges and Solutions

Infrastructure Limitations

Despite success, the system faces ongoing challenges:

ICU capacity constraints: Limited critical care beds during peak demand periods
Equipment standardization: Variability in monitoring and support equipment across facilities
Staff training: Continuous education requirements for rotating ICU staff

Technological Solutions

Tamil Nadu has leveraged technology to address these challenges:

Telemedicine consultation: Remote expert consultation for donor management decisions
Mobile applications: Real-time coordination apps for transport teams and hospitals
Data analytics: Predictive modeling for organ allocation and transport optimization

Pearl #5: Implement a "donor champion" program - designate one ICU physician per shift as the primary contact for all donor-related decisions to ensure consistency and accountability.

Future Directions and Innovations

Expanding the Model

The Tamil Nadu model is being adapted and implemented in other Indian states and internationally:

Kerala and Karnataka: Modified Green Corridor systems based on Tamil Nadu's protocols
International collaborations: Consultation with organ procurement organizations in the United States and Europe
Technology transfer: Sharing of protocols and training materials with other regions

Emerging Technologies

Future enhancements may include:

Machine perfusion: Ex-vivo organ perfusion systems to extend viable transport times
Artificial intelligence: AI-powered donor matching and transport optimization
Advanced monitoring: Continuous biomarker monitoring for real-time organ viability assessment

Hack #3: Develop simulation-based training programs for Green Corridor scenarios. Regular drills involving all stakeholders (ICU staff, transport teams, police) improve coordination and reduce errors during actual organ transports.

Global Implications and Lessons Learned

Key Success Factors

Analysis of Tamil Nadu's success reveals several critical success factors applicable globally:

Political commitment: Strong governmental support for organ donation initiatives
Systematic protocols: Evidence-based, standardized approaches to donor management
Multi-stakeholder coordination: Effective collaboration between healthcare, law enforcement, and administrative agencies
Continuous quality improvement: Regular audits and protocol refinements based on outcomes data
Cultural adaptation: Sensitivity to local cultural and religious factors

Scalability Considerations

The Tamil Nadu model's scalability depends on several factors:

Healthcare infrastructure: Adequate ICU capacity and critical care expertise
Transportation networks: Efficient road and air transport systems
Regulatory framework: Supportive legal and administrative structures
Cultural acceptance: Community awareness and acceptance of organ donation

Oyster #3: Success requires changing institutional culture, not just protocols. Focus on building enthusiasm and ownership among ICU staff rather than just compliance with guidelines.

Recommendations for Critical Care Practitioners

Immediate Implementation Strategies

Critical care physicians can immediately implement several evidence-based strategies:

Standardize donor management protocols based on Tamil Nadu's evidence-based approaches
Establish clear communication pathways with transplant coordinators and organ procurement organizations
Implement systematic family counseling approaches with dedicated trained personnel
Develop transport coordination protocols with local emergency medical services

Medium-term System Development

Healthcare systems should consider:

Investment in transport infrastructure including dedicated ambulances and air transport capabilities
Technology platform development for real-time coordination and communication
Staff training programs focused on donor management and family communication
Quality metrics implementation with regular outcome monitoring and improvement

Pearl #6: Start small but think systematically. Even implementing standardized donor management protocols in a single ICU can significantly improve organ utilization rates and patient outcomes.

Conclusion

Tamil Nadu's Green Corridors represent a transformative model for organ donation that demonstrates how systematic critical care excellence, innovative logistics, and coordinated stakeholder engagement can dramatically improve transplantation outcomes. The state's achievement of transporting over 200 hearts annually within 6-hour ischemic windows reflects not just efficient transport systems, but sophisticated ICU-based donor management protocols that optimize organ viability throughout the donation process.

The critical care community has much to learn from Tamil Nadu's evidence-based approach to donor management, including standardized protocols for cardiovascular support, respiratory management, and hormonal replacement therapy. The integration of advanced monitoring strategies, pharmacological optimization, and systematic quality improvement has created a replicable model for excellence in organ donation.

As the global need for organ transplantation continues to grow, Tamil Nadu's Green Corridors provide a roadmap for how critical care physicians can contribute to expanding organ availability through clinical excellence, systematic protocols, and innovative logistics coordination. The success of this model demonstrates that with appropriate commitment, resources, and systematic implementation, dramatic improvements in organ donation outcomes are achievable in diverse healthcare settings worldwide.

The pearls, oysters, and clinical hacks presented in this review provide actionable insights for critical care practitioners seeking to improve organ donation outcomes in their own institutions. By implementing evidence-based donor management protocols, developing systematic transport coordination, and fostering multi-stakeholder collaboration, the critical care community can help expand access to life-saving organ transplantation for patients worldwide.

References

Shroff S, Navin S, Abraham G, et al. Cadaver organ donation and transplantation - an Indian perspective. Transplant Proc. 2003;35(1):15-17.
Ramanathan R, Narendran S. Organ donation in India - current scenario and the way forward. J Postgrad Med. 2019;65(4):189-195.
Government of Tamil Nadu. Tamil Nadu Organ and Tissue Transplantation Organisation Annual Report 2022-23. Chennai: Department of Health and Family Welfare; 2023.
Westphal GA, Caldeira Filho M, Vieira KD, et al. Guidelines for the assessment and acceptance of potential brain-dead organ donors. Rev Bras Ter Intensiva. 2016;28(3):220-255.
Meyfroidt G, Gunst J, Martin-Loeches I, et al. Management of the brain-dead donor in the ICU: general and specific therapy to improve transplantable organ quality. Intensive Care Med. 2019;45(3):343-353.
Kotloff RM, Blosser S, Fulda GJ, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291-1325.
McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. Br J Anaesth. 2012;108 Suppl 1:i96-107.
Tamil Nadu Transplantation Authority. Green Corridor Protocol Manual. 4th ed. Chennai: Government of Tamil Nadu; 2023.
Nagendran M, Heng AE, Ong CS, et al. Systematic review of organ donation rates and outcomes following implementation of opt-out legislation. Transplantation. 2021;105(8):1849-1857.
Domínguez-Gil B, Haase-Kromwijk B, Van Leiden H, et al. Current situation of donation after circulatory death in European countries. Transpl Int. 2011;24(7):676-686.

Conflicts of Interest: The authors declare no conflicts of interest.

Funding: This review received no specific funding.